Robert Bhisitkul and Tejal Desai are developing a solution to improve lives of people suffering from eye diseases like glaucoma and macular degeneration. Desai is working on developing a tiny, flexible, implantable film which can deliver conventional medicine and complex anti-body based drugs used for retinal therapies.
The purpose is to remove inefficacies like monthly eye injections which can cause infections, use of eye drops throughout the day and frequent visits to doctors. Both of them have a vision to create a product that will be cost –effective, increase therapeutic effectiveness and reduce visits to one or two per year to the doctor. They have put their project and LaunchPad, knowing that they need help navigating regulatory pathways and perspective from possible investors. Both of them are based at UCSF with the Catalyst Program. This gives them the desired proximity and perspective to develop the same in a supportive environment.
No comments:
Post a Comment